Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2019-08-20
Target enrollment:
Participant gender:
Summary
This is a multi-institutional, randomized, open-label phase II study of pembrolizumab
compared to topotecan, administered to patients with SCLC who have progressed or relapsed
after first-line treatment with etoposide and platinum. Patients will be randomized in a 2:1
fashion to receive pembrolizumab or topotecan. Participants in the topotecan arm that
progress will be allowed to cross-over to the pembrolizumab arm.